What are the considerations for using Depakote (valproate) in a geriatric patient with Alzheimer's disease?

Depakote (Valproate) Should Be Avoided in Alzheimer's Patients

Valproate should not be used in elderly patients with Alzheimer's disease due to significant safety concerns, lack of efficacy, and availability of safer alternatives. 1, 2, 3

Critical Safety Concerns

The FDA label specifically warns about somnolence in elderly dementia patients, noting that in a double-blind trial (mean age 83 years), a significantly higher proportion of valproate patients experienced somnolence compared to placebo, with associated risks of dehydration, reduced nutritional intake, and weight loss. 2 Discontinuations for somnolence were significantly higher than placebo, and patients with these events tended to have lower baseline albumin, lower valproate clearance, and higher BUN. 2

Additional serious risks include:

• Thrombocytopenia: 27% of patients receiving ~50 mg/kg/day had platelet counts ≤75 x 10⁹/L, with risk increasing significantly at valproate concentrations ≥110 μg/mL (females) or ≥135 μg/mL (males). 2
• Suicidal ideation: AEDs including valproate increase risk of suicidal thoughts and behavior across all age groups (5-100 years). 2
• Drug interactions: Carbapenem antibiotics can reduce valproate to subtherapeutic levels, causing loss of seizure control. 2

Lack of Evidence for Efficacy

A Cochrane systematic review concluded that valproate preparations cannot be recommended for treatment of agitation in dementia. 3 The review found:

• Low-dose sodium valproate is ineffective for treating agitation in demented patients 3
• High-dose divalproex sodium is associated with unacceptable rates of adverse effects 3
• In one trial, 54% of treated patients dropped out compared to 29% of controls, with 22% discontinuing due to adverse effects 3

Individual studies show only modest effectiveness at best, with open-label trials reporting minimal improvement and significant tolerability issues. 4, 5, 6

Recommended Alternatives

First-Line Approach: Non-Pharmacological Interventions

The American Academy of Family Physicians and American Geriatrics Society strongly recommend exhausting non-pharmacological strategies before any psychotropic medications. 1, 7, 8

Implement these specific interventions:

• Establish predictable routines with consistent exercise, meal, and sleep schedules 7
• Use the "three R's" approach: Repeat, Reassure, and Redirect 7
• Environmental modifications: eliminate hazards, install safety locks, use calendars and labels 7
• Structured exercise program: walking, aerobic exercise, resistance training, balance exercises 7

Second-Line: Appropriate Pharmacological Options

If behavioral symptoms persist despite non-pharmacological interventions:

For cognitive symptoms and mild behavioral disturbances:

• Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) are first-line and may improve neuropsychiatric symptoms 1, 7, 8
• Donepezil: start 5 mg daily, increase to 10 mg after 4-6 weeks 7
• Memantine for moderate-to-severe disease, alone or combined with cholinesterase inhibitors 1, 7

For persistent agitation/neuropsychiatric symptoms:

• SSRIs (citalopram, sertraline) are recommended for agitation that persists despite non-pharmacologic interventions 8
• Antipsychotics should be avoided due to increased mortality risk, used only when patients pose hazards to self or others, and discontinued after 3 months if used 1, 8

Medications to Avoid in This Population

The American Geriatrics Society 2019 Beers Criteria specifically identifies medications that worsen cognitive function in dementia:

• Anticholinergics (diphenhydramine, hydroxyzine, cyclobenzaprine, oxybutynin): cause delirium, slowed comprehension, sedation, falls 1
• Benzodiazepines: sedating, cognitive impairing, unsafe mobility with falls, habituation 1
• Long-term antipsychotics: avoid most sedating agents as they worsen cognitive function 1

Clinical Pitfalls to Avoid

1. Do not use valproate for behavioral symptoms in dementia - it lacks efficacy and carries unacceptable risks in this population 2, 3
2. Monitor for polypharmacy - the example case in the guidelines shows a patient on 15 medications, increasing risk of adverse effects and interactions 1
3. Optimize comorbid conditions first - treat depression, hypertension, diabetes, correct vision/hearing deficits, as these worsen cognitive function 7
4. Avoid tight glycemic control - appropriate HbA1c target may be 8-9% in elderly with limited life expectancy 1
5. Consider deprescribing - cholinesterase inhibitors should be discontinued in severe/end-stage dementia or if no meaningful benefit observed 1